PureTech Health plc (OTCMKTS:PTCHF – Get Rating) was down 14.9% on Thursday . The stock traded as low as $2.43 and last traded at $2.52. Approximately 1,107 shares traded hands during mid-day trading, a decline of 81% from the average daily volume of 5,933 shares. The stock had previously closed at $2.96.
PureTech Health Trading Down 14.9 %
The business has a fifty day moving average price of $2.73 and a 200 day moving average price of $2.48.
About PureTech Health
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions.
- Get a free copy of the StockNews.com research report on PureTech Health (PTCHF)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.